Previous close | 2.0000 |
Open | 2.0000 |
Bid | 1.9500 |
Ask | 2.2000 |
Strike | 50.00 |
Expiry date | 2025-02-21 |
Day's range | 2.0000 - 2.0000 |
Contract range | N/A |
Volume | |
Open interest | 28 |
QIAGEN adds over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications // QIAcuity digital PCR enables accurate and sensitive detection of low-abundance pathogens, copy number alterations and identification of rare mutations // Portfolio expansion and partnerships support increased adoption of QIAcuity across multiple application areasVenlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN
To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.
QIAGEN and Bio-Manguinhos/Fiocruz team up to enhance malaria and dengue detection in Brazil's national screening programs.